Generic Name: Paclitaxel albumin bound
Originator’s name: Abraxane®
Paclinab is a microtubule inhibitor indicated for the treatment of patients with Metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer, Metastatic adenocarcinoma of pancreas. It is recommended by guidelines such as NCCN and ESMO as first line regimens in metastatic pancreatic cancer in combination with gemcitabine and in nonsmall cell lung cancer in combination with carboplatin.


  • Metastatic Breast Cancer: Paclinab is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
  • Non-Small Cell Lung Cancer: Paclinab is indicated for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
  • Adenocarcinoma of the Pancreas: Paclinab is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.


Generic Name: Palbociclib
Originator’s name: Ibrance®
Palbociclib is the first FDA-approved medication in a class of therapy called CDK 4/6 inhibitors. Taken in combination with certain hormonal therapies, Palbocap works to put the brakes on cell growth and division in hormone receptor positive, HER2- metastatic breast

Palbocap is a prescription medicine used to treat hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)- negative breast cancer that has spread to other parts of the body (metastatic) in combination with:

  • An aromatase inhibitor as the first hormonal based therapy in women who have gone through menopause.
  • Fulvestrant in women with disease progression following hormonal therapy


Generic Name: Pralatrexate
Originator’s name: Folotyn®
Pralatrexate is a folate analogue metabolic inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated.

Treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate.


Generic Name: Naltrexone (extended release)
Originator’s name: Vivitrol®
Exopio is an opioid receptor antagonist with highest affinity for the mu opioid receptor. Naltrexone has little or no opioid agonist activity. Treatment with Exopio should be part of a comprehensive management program that includes psychosocial support.


  •  Opioid Dependence
  • Alcohol Dependence


Generic Name: Trastuzumab Emtansine
Originator’s name: Kadcyla®
Padynex is a HER2 antibody drug conjugate. The antibody portion is Trastuzumab, which is humanized anti-HER2 IgG1, and produced in the mammalian Chinese Hamster Ovary cells. The drug portion is DM1, which is a maytansine derivative that inhibits microtubules. These two portions are covalently connected by 4-[N-maleimidomethyl] cyclohexane-1-carboxylate (MCC), which is a stable thioether linker. Together MCC and DM1 are called Emtansine and are produced by chemical synthesis. Trastuzumab Emtansine binds to the HER2 receptor’s sub-domain IV and goes into the cell by receptormediated endocytosis. Lysosomes degrade Trastuzumab Emtansine and release
DM1. DM1 binds to tubulin in microtubules and inhibits microtubule function producing cell arrest and apoptosis. As well, similar to Trastuzumab, in vitro studies have shown that both HER2 receptor signalling inhibition and antibodydependent cytotoxicity are mediated by Trastuzumab Emtansine



  • Monotherapy for the treatment of HER2- positive, unresectable, locally advanced or metastatic breast cancer, in adult patients who have previously received trastuzumab and a taxane separately or in combination (initiated by a specialist)
  • Monotherapy for the treatment of HER2- positive, unresectable, locally advanced or metastatic breast cancer, in adult patients who have developed disease recurrence during or within 6 months of completing adjuvant therapy (initiated by a specialist)


Generic Name: Trientine
Originator’s name: Syprine®
Trientine hydrochloride is a chelating compound for removal of excess copper from the body. It is used for the treatment of Wilson’s disease which is genetic metabolic defect


  • Wilson’s disease in patients intolerant of


Generic Name: Ciprofloxacin
Originator’s name: Cipro IV®
Ciprofloxacin has in vitro activity against a wide range of gram-negative and gram-positive microorganisms. The bactericidal actions of Ciprofloxacin result from inhibition of the enzymes topoisomerase II (DNA gyrase) and
topoisomerase IV, which are required for bacterial DNA replication, transcription, repair and recombination


Adult Patients:

  • Urinary Tract infection
  • Lower Respiratory tract infection
  • Nosocomial Pneomonia infection
  • Skin and skin stracture infection
  • Bone and joint infection
  • Intra-abdominal infection
  • Acute sinusitis infection
  • Chronic Bacterial Prostatitis infection
  • Empirical Therapy in febrile infection
  • Neutropenic patiens infection
  • Inhalational antrax infection (post

Pediatric patients (1 to 17 years of age):

  • Inhalation Anthrax infection (PostExposure)
  • Infections and Pyelonephritis due to
    Escherichia coli (Patients from 1 to 17
    years of age)
  • Complicated Urinary Tract infection


Generic Name: Pantoprazole
Originator’s name: Protonix® IV

Pantoprazole is a PPI that suppresses the final step in gastric acid production by covalently binding to the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell.


  • Short-Term Treatment of Erosive
    Esophagitis Associated with
    Gastroesophageal Reflux Disease (GERD)
  • Maintenance of Healing of Erosive
  • Pathological Hypersecretory Conditions
    Including ZollingerEllison Syndrome
  • Duodenal ulcer
  • Gastric ulcer


Generic Name: Esomeprazole
Originator’s name: NEXIUM® I.V
Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+ /K+ ¬ ATPase in the gastric parietal cell. Esomeprazole is the s-isomer of omeprazole. The S- and R-isomers of omeprazole are protonated and converted in the acidic compartment of the parietal cell forming the active inhibitor, the achiral sulphenamide. By acting specifically on the proton pump, Esomeprazole blocks the final step in acid production, thus reducing gastric acidity. This effect is dose-related up to a daily dose of 20 to 40mg and leads to inhibition of gastric acid secretion.


  • Gastro-oesophageal reflux disease (in the
    presence of erosive reflux oesophagitis)
  • Symptomatic treatment of gastrooesophageal
    reflux disease (in the
    absence of oesophagitis)
  • Severe peptic ulcer bleeding (following
    endoscopic treatment)
  • NSAID-associated gastric ulcer
  • Prophylaxis of NSAID-associated gastric
    or duodenal ulcer


Generic Name: Anakinra
Originator’s name: Kineret
LeukinRA is a recombinant, nonglycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra). LeukinRA differs from native human IL-1Ra in that it has the addition of a single methionine residue at its amino terminus. LeukinRA consists of 153 amino acids and has a molecular weight of 17.3 kilodaltons. It is produced by recombinant DNA technology using an E coli bacterial expression system.


  • For the reduction in signs and symptoms
    and slowing the progression of structural
    damage in moderately to severely active
    rheumatoid arthritis (RA), in patients 18
    years of age or older who have failed 1 or
    more disease modifying antirheumatic
    drugs (DMARDs)
  • Can be used alone or in combination with
    DMARDs other than Tumor Necrosis
    Factor (TNF) blocking agents
  • For the treatment of Neonatal-Onset
    Multisystem Inflammatory Disease


Generic Name: Beractant
Originator’s name: Survanta®
Beraksurf® is a generic form of medicine exists in the market with the name of Survanta® (Beractant). However it could be a good substitute for other surfactants exist in the market. Beraksurf® is a bovine pulmonary surfactant containing bovine lung extract which used for the treatment of Respiratory Distress Syndrome (RDS) in premature infants. Beractant contains a mixture of phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins such as SP-B and SP-C.


  • Prevention and treatment of respiratory
    distress syndrome (RDS) in premature